SCHEMBL2117940

SCHEMBL2117940

Cc1ccn(-c2ccc(C)c(NS(=O)(=O)c3ccc(O)cc3)c2)n1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 4/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GHSR Q92847 2/20 0.43
ALDH1A1 P00352 4/20 0.43
GAA P10253 3/20 0.43
GFER P55789 1/20 0.43
CYP2C9 P11712 2/20 0.42
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
POLB P06746 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYTH2 Q99418 1/20 0.40
EDNRA P25101 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119724 0.88 TERT (0.51) KAT6AMEN1KMT2AGHSRALDH1A1
SCHEMBL2118406 0.88 ALDH1A1 (0.51) KAT6AMEN1KMT2AGHSRALDH1A1
SCHEMBL2118542 0.80 MEN1 (0.52) MEN1KMT2AGHSRALDH1A1GAA
SCHEMBL2118397 0.78 ALDH1A1 (0.45) MEN1KMT2AGHSRALDH1A1GAA
SCHEMBL597553 0.72 HTT (0.56) KAT6AKMT2AALDH1A1GAAMAPT
SCHEMBL2118662 0.70 ALDH1A1 (0.61) MEN1KMT2AALDH1A1GAAGFER
SCHEMBL2119832 0.70 ALDH1A1 (0.47) MEN1KMT2AALDH1A1GAAGFER
SCHEMBL2117978 0.70 MAPT (0.45) ALDH1A1GAAGFERCYP2C9MAPT
SCHEMBL2120070 0.69 MAPT (0.54) KAT6AALDH1A1GAAMAPTLMNA
SCHEMBL2118702 0.69 MAPT (0.49) MEN1KMT2AGHSRALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 KAT6A 2893/4885MEN1 3114/4885KMT2A 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.